HOME >> BIOLOGY >> NEWS
Three molecular-targeted compounds show promise against cancers

BOSTON (November 20, 2003) -- Early clinical studies show that a new generation of drugs that target signaling pathways -- the internal channels through which cancer cell growth is controlled -- and the body's own production of tumor-suppressing proteins hold promise for the treatment of a variety of tumors. Patient trials evaluated drug tolerance and potential anti-tumor activity against a variety of cancers such as renal cell, colorectal and non-Hodgkin's lymphoma of three compounds. The studies were presented today at the International Conference on Molecular Targets and Cancer Therapeutics organized by the American Association of Cancer Research (AACR), National Cancer Institute (NCI) and European Organization for Research and Treatment of Cancer (EORTC) in Boston.

Phase II study of SU11248 in patients with advanced malignancies incorporating PET imaging: Abstract 663

An experimental pill aimed at several important signaling molecules involved in angiogenesis and cell growth produced evidence of tumor shrinkage and arrest in tumor growth in patients with advanced, refractory cancers. Dr. Guy C. Toner, Centre for Developmental Cancer Therapeutics in Melbourne, Australia, presented preliminary results from 41 patients in the clinical study.

The compound, called SU11248, inhibits signaling proteins called tyrosine kinases, which help tumor cells, its surrounding cells, and blood vessels that feed them, grow. Specifically, SU11248 is designed to target three important kinases VEGFR, PDGFR and KIT.

"The study employed an imaging technique, called PET scanning, to assess biological response and correlated the results with conventional responses and with known angiogenesis biomarkers, such as circulating sVEGF," said Dr. Toner.

The study enrolled patients with a variety of tumor types, including colorectal, sarcoma, melanoma, and renal cancers that were refractory to standard therapies. SU11248 was administered as a t
'"/>

Contact: Warren Froelich
froelich@aacr.org
617-954-2908
American Association for Cancer Research
20-Nov-2003


Page: 1 2 3 4

Related biology news :

1. Three new South American fish identified
2. Three personal ads for physics
3. Three genes linked to psoriasis susceptibility identified on chromosome 17
4. Three Pacific Northwest National Laboratory inventions win R&D 100 Awards
5. Three Gorges Dam is an opportunity for ecoscience
6. Three tourist experiences named best worldwide for environmental, social responsibility
7. Three inferior prefrontal regions of the brain found receptive to somatosensory stimuli
8. Three dimensional structure of a protein transport machine
9. Three studies released this week shed new light on eating nuts for good health
10. Three nations agree to share ice core thatmay yield clues about nature of Lake Vostok
11. Three-D images shed light on first steps of RNA synthesis

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/3/2020)... ... 03, 2020 , ... Litmus Health , the research-ready ... of the company’s security practices has been completed. The assessment deemed Litmus infrastructure ... evaluation reviewed Litmus’ processes and systems, assessing them to see whether they adhere ...
(Date:8/23/2020)... , ... August 21, 2020 , ... ... Corporation has been published and is now available on the company’s global ... diffraction—serves the X-ray analysis community, presenting current news and crystallographic research. , ...
(Date:8/12/2020)... , ... August 11, 2020 , ... ... based in Princeton, NJ, have entered into license agreements with Housey Pharma’s HMI ... Both Roche and J&J have annual Research and Development spending in excess ...
Breaking Biology News(10 mins):
(Date:8/15/2020)... SCOTTSDALE, Ariz. (PRWEB) , ... August 13, 2020 ... ... 4254 on its annual Inc. 5000 list, the most prestigious ranking of the ... successful companies within the American economy’s most dynamic segment—its independent small businesses. Intuit, ...
(Date:8/3/2020)... PHILADELPHIA (PRWEB) , ... August 03, 2020 , ... ... data collection, today announced Jim Corrigan, President and CEO has been named one ... a broad cross-section of industry sectors, PharmaVoice 100 honorees are selected based on ...
(Date:7/31/2020)... ... July 29, 2020 , ... Anomet Products ... three different materials for use with CRM, neurostimulation, vascular, and related devices. , ... meet specific design requirements, performance, and cost criteria; especially where solid wire is ...
(Date:7/22/2020)... (PRWEB) , ... July 22, 2020 , ... Join experts ... John Lorenc, Sr. Manager Regulatory Solutions, in a one hour live webinar ... the regulating body in China for drugs and medical devices. Specifically, for medical devices, ...
Breaking Biology Technology:
Cached News: